11-19 更新 实时
首页/ AI 大模型/ 正文

CataX AI 融资 4000 万元,将智能体引入临床药物开发

AI 大模型 来源:TechNode 2026-11-16 14:36 0 阅读 机器翻译
CataX AI 融资 4000 万元,将智能体引入临床药物开发

Shanghai-based CataX AI has raised RMB 40 million in a seed round from Qiming Venture Partners, which incubated the startup and was the sole investor. CataX AI plans to license or co-develop drug candidates at the preclinical or early clinical stage and advance them through clinical proof of concept.

The company calls its operating model “Clinical-of-One.” A clinical lead oversees each program with support from specialists and AI agents that review research, draft documents and process data. Human experts make key decisions, and the company aims to reuse what it learns across programs. Founder and CEO Wang Zilong has a background in clinical medicine and AI research at Microsoft Research Asia, while co-founder Jiang Zhemin has more than 15 years of clinical development experience. [TechNode reporting]

正文保留英文原文,标题与摘要由机器翻译。

本文由采集器自动同步

原文发布于 TechNode(CataX AI raises RMB 40 million to bring AI agents into clinical drug development),标题、摘要与正文由机器翻译,术语按行业惯例统一,未经人工逐句校订。

阅读原文 ↗